Cyclacel Pharmaceuticals Reports First Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil falls as Trump comments on Iran talks ease supply fears
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
- US consumer sentiment near record low as frustration over economy mounts
- 8.0 Mag. Earthquake 14 Km Sw Of Pitaloza Arriba Panama - USGS
- Powerful quake hits Panama, damages homes; canal operations normal
- SpaceX to acquire Grain Management's 800 MHz spectrum portfolio
- CoreWeave stock drops on dilution fears and debt concerns
Cyclacel Pharma (CYCC) Reports Q1 Loss of $0.38
May 14, 2018 4:16 PM EDTCyclacel Pharma (NASDAQ: CYCC) reported Q1 EPS of ($0.38), versus ($0.12) reported last year.
As of March 31, 2018, cash and cash equivalents totaled $21.7 million, compared to $23.9 million as of December 31, 2017. The decrease of $2.2 million was primarily due to net cash used in operating activities.
For... More



